CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Survival of Patients With Severe ARDS Treated Without ECMO

Published: Mon, 18 Jun 2018 12:00:00 EDT
A new study explores the survival rates of patients with severe ARDS who were managed without extracorporeal membrane oxygenation.
American Journal of Critical Care

Training for Adolescents With Special Healthcare Needs

Published: Mon, 18 Jun 2018 12:00:00 EDT
Could this new provider training program help adolescents and young adults with special healthcare needs successfully transition from pediatric to adult care?
Pediatric Nursing

ADT and Prolongation of QTc Interval in Prostate Cancer

Published: Mon, 18 Jun 2018 12:00:00 EDT
Could changes in QTc duration during androgen deprivation therapy for prostate cancer help explain the increased risk for cardiovascular events in these patients?
Journal of the Endocrine Society
Displaying results 4-6 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

X4 targets year-end start for phase 3 WHIM trial after determining dose in midphase readout

Published: Fri, 15 Jun 2018 12:26:17 +0000
X4 Pharmaceuticals has established the X4P-001-RD dose to take forward into the pivotal stage of its phase 2/3 WHIM syndrome trial. Setting the dose of the CXCR4 inhibitor tees X4 up to start the phase 3 portion of the rare primary immunodeficiency disease trial before the end of the year.

Selecta unveils more data on its gout treatment, commits to phase 3 study launch this year

Published: Thu, 14 Jun 2018 18:14:06 +0000
Selecta Biosciences presented more new data from an ongoing phase 2 trial of its enzyme treatment for gout, which the company said outperformed standard treatment and has convinced it to soldier on to a phase 3 clinical program before the end of the year.

All-in-one CAR-T packages therapy and safety in one molecule

Published: Thu, 14 Jun 2018 16:55:04 +0000
French biotech Cellectis has devised a form of CAR-T that contains its therapeutic effects with a safeguard in a single molecule. The company believes the invention will pave the way to off-the-shelf CAR-T treatments.
Displaying results 4-6 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top